Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-12-16 Capital/Financing Update
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Update - Proposed issue of Securities - NTI 6 pages 30.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed issue of securities by Neurotech International Limited. It includes details about the securities, approval dates, and references to previous announcements and shareholder meetings. The content focuses on the issuance of new options and related terms, consistent with capital raising or financing activities. There is no indication that this is a full financial report, audit, or earnings release. The document is not a report publication announcement but a detailed update on a securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-12-16 English
Update - Proposed issue of Securities - NTI 7 pages 34.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed issue of securities by Neurotech International Limited. It includes details about the securities to be issued, approval dates, conditions, and other related information. The document references an Appendix 3B, which is a standard form used in Australian Securities Exchange (ASX) announcements for new securities issues. The content is focused on the update to a previous announcement about the securities issue, confirming the actual issue date and providing detailed terms of the securities. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full report but an update announcement related to capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-12-16 English
Change of Director's Interest Notice x 3 7 pages 460.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including options and shares held by directors and related entities. The document includes specifics about the nature of the interests, dates of changes, and securities involved. There is no financial performance data, earnings information, or management discussion. The content is focused on reporting personal share transactions by company directors. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is over 12,000 characters, indicating it is a full notice rather than a brief announcement. Therefore, the correct classification is DIRS.
2020-12-16 English
Disclosure Document 42 pages 462.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus' and details a Placement Offer for shares and options in Neurotech International Limited. It includes information about the offer price, number of shares, terms of the offer, risk factors, company overview, and other details typical of a securities offering document. It is a transaction-specific prospectus issued under section 713 of the Corporations Act, intended to raise capital through share issuance. This type of document is a formal offer to investors to subscribe for new securities and is not a financial report, earnings release, or management discussion. It is clearly a capital raising document related to financing activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length and detail confirm it is the actual prospectus, not just an announcement of it, so it is not a report publication announcement or regulatory filing.
2020-12-15 English
Appendix 2A 15 pages 221.5KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of new securities due to options being exercised and shares issued in lieu of supplier fees. The document is a regulatory announcement related to capital markets and securities issuance, specifically an application for quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing to the exchange. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive filing, not a brief announcement or certification.
2020-12-10 English
Further Success with Preliminary In-vitro Studies 4 pages 129.5KB
Regulatory Filings Classification · 85% confidence The document is a detailed announcement from Neurotech International Limited about preliminary results from in-vitro studies on their proprietary cannabis leads. It includes scientific data, assay results, and references to ongoing and future studies. The document also mentions a conference call related to the announcement. There is no indication that this is a full financial report, audit report, or regulatory filing. It is not a transcript of a call but an announcement of scientific study results. The content is focused on research progress and preliminary scientific findings rather than financial or governance matters. Given the nature of the content and the presence of a conference call announcement, the document best fits the category of a Call Transcript (CT) announcement or related to a conference call. However, since the document itself is not a transcript but an announcement including scientific results and a conference call invitation, it is not a pure call transcript. The document is primarily a scientific and corporate announcement with a conference call component. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories, especially since it is a corporate announcement of study results and a conference call, not a financial or governance report.
2020-11-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.